Global Pharmaceutical Contract Manufacturing Market

Pharmaceutical Contract Manufacturing Comprehensive Study by Type (Active Pharmaceutical Ingredients (API), Finished Dosage Formulations (FDF) (Tablet, Capsule, Oral Liquids, Parenteral/Injectable, Others), Advanced Drug Delivery Products, Over The Counter (OTC) Medicines and Nutritional Products, Others), Application (Pharmaceutical, Biopharmaceutical), End User (Sterile, Non-sterile) Players and Region - Global Market Outlook to 2026

Pharmaceutical Contract Manufacturing Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 7.5%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Pharmaceutical Contract Manufacturing Market Scope
Pharmaceutical Contract Manufacturing refers to contract basis services for drug development and manufacturing. It includes mainly manufacturing of solid and liquid dosage forms as well as the injectable. Pharmaceutical companies are focusing on contract manufacturing as it saves the labor cost such as training, wages, and also it provides quality pharmaceutical manufacturing solutions. Further, the increasing number of patients with chronic diseases and focus towards prevention of disease rather treatment have led to a rise in demand for novel drugs and treatment. For instance, According to the World Health Organization (WHO) 2018 report, cardiovascular diseases accounted for nearly 836,546 deaths in the United States and 3.9 million deaths in Europe. And cancer led to 9.6 million deaths globally in 2018. Further, increasing investment in pharmaceutical contract manufacturing and government favorable policies are expected to strengthen the market during the forecasted period.

According to AMA, the Global Pharmaceutical Contract Manufacturing market is expected to see growth rate of 7.5%

Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Pharmaceutical Contract Manufacturing market throughout the predicted period.

Thermo Fisher Scientific (United States), Catalent (United States), Lonza (Switzerland), Evonik Industries (Germany), Teva Pharmaceutical Industries (Israel), Boehringer Ingelheim BioXcellence (Germany), Famar S.A. (Greece), Fareva Group (France), Vetter Pharma International (Germany), Mylan (United States), Recipharm (Sweden), Aesica Pharmaceuticals (United Kingdom), Pharmaceutical Product Development LLC (United States), AbbVie (United States) and Baxter BioPharma Solutions (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are QuintilesIMS (United States), Dalton Pharma Services (Canada), Grifols S.A (Spain), Ligand Pharmaceuticals, Inc. (United States), Valeant Pharmaceuticals International Inc. (Canada) and West Pharmaceutical Services, Inc. (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
The study have segmented the market of Global Pharmaceutical Contract Manufacturing market by Type (Active Pharmaceutical Ingredients [API], Finished Dosage Formulations (FDF) [Tablet, Capsule, Oral Liquids, Parenteral/Injectable, Others], Advanced Drug Delivery Products, Over The Counter [OTC] Medicines and Nutritional Products and Others), by Application (Pharmaceutical and Biopharmaceutical) and Region with country level break-up.

On the basis of geography, the market of Pharmaceutical Contract Manufacturing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
21st February 2019, Teva Pharmaceutical Industries Ltd. an Israeli multinational pharmaceutical company collaborated with Insilico Medicine, an American biotechnology company. This collaboration will enhance the production processes for Teva’s biopharmaceutical therapeutics by using Insilico’s technology for predictive biomanufacturing.

“According to Food and Drug Administration (FDA), each party engaged in the manufacture of a drug is responsible for ensuring compliance with Current Good Manufacturing Practice regulations (CGMP) for the manufacturing activities it performs. For both owners and contract facilities that conduct manufacturing operations, CGMP “includes the implementation of oversight and controls over the manufacture of drugs to ensure quality, including managing the risk of and establishing the safety of raw materials, materials used in the manufacturing of drugs, and finished drug products.” The FD&C Act also prohibits any person from introducing or delivering for introduction an adulterated or misbranded drug into interstate commerce."

Market Trend
  • Rise in Demand of Generic Drugs and Complex Pharmaceutical Products
  • Emphasizing On Development of Cost-Effective Pharmaceuticals

Market Drivers
  • Increasing Geriatric Population and Prevalence of Chronic Diseases
  • Growing R&D Activities Led to Rise in Number of Pharmaceutical Products in the Pipeline

Opportunities
  • Growing Demand for Outsourcing Services for Healthcare from Developing Economies
  • Growing Biopharmaceutical Industry

Restraints
  • Huge Initial Investment for Pharmaceutical Contract Manufacturing Services
  • Data Security and Privacy Concerns Associated with Pharmaceutical Contract Manufacturing

Challenges
  • Lack of Advance Healthcare Facilities in Emerging Countries


Key Target Audience
Biotechnology and pharmaceutical companies, Government agencies, Contract research organizations, Academic and research institutions, Hospitals and diagnostic centers, Market research and consulting firms, Venture capitalists and investors and Others

Report Objectives / Segmentation Covered

By Type
  • Active Pharmaceutical Ingredients [API]
  • Finished Dosage Formulations (FDF) [Tablet, Capsule, Oral Liquids, Parenteral/Injectable, Others]
  • Advanced Drug Delivery Products
  • Over The Counter [OTC] Medicines and Nutritional Products
  • Others
By Application
  • Pharmaceutical
  • Biopharmaceutical
By End User
  • Sterile
  • Non-sterile

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Geriatric Population and Prevalence of Chronic Diseases
      • 3.2.2. Growing R&D Activities Led to Rise in Number of Pharmaceutical Products in the Pipeline
    • 3.3. Market Challenges
      • 3.3.1. Lack of Advance Healthcare Facilities in Emerging Countries
    • 3.4. Market Trends
      • 3.4.1. Rise in Demand of Generic Drugs and Complex Pharmaceutical Products
      • 3.4.2. Emphasizing On Development of Cost-Effective Pharmaceuticals
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pharmaceutical Contract Manufacturing, by Type, Application, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Pharmaceutical Contract Manufacturing (Value)
      • 5.2.1. Global Pharmaceutical Contract Manufacturing by: Type (Value)
        • 5.2.1.1. Active Pharmaceutical Ingredients [API]
        • 5.2.1.2. Finished Dosage Formulations (FDF) [Tablet, Capsule, Oral Liquids, Parenteral/Injectable, Others]
        • 5.2.1.3. Advanced Drug Delivery Products
        • 5.2.1.4. Over The Counter [OTC] Medicines and Nutritional Products
        • 5.2.1.5. Others
      • 5.2.2. Global Pharmaceutical Contract Manufacturing by: Application (Value)
        • 5.2.2.1. Pharmaceutical
        • 5.2.2.2. Biopharmaceutical
      • 5.2.3. Global Pharmaceutical Contract Manufacturing by: End User (Value)
        • 5.2.3.1. Sterile
        • 5.2.3.2. Non-sterile
      • 5.2.4. Global Pharmaceutical Contract Manufacturing Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Pharmaceutical Contract Manufacturing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher Scientific (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Catalent (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Lonza (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Evonik Industries (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva Pharmaceutical Industries (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Boehringer Ingelheim BioXcellence (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Famar S.A. (Greece)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Fareva Group (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Vetter Pharma International (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mylan (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Recipharm (Sweden)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Aesica Pharmaceuticals (United Kingdom)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Pharmaceutical Product Development LLC (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. AbbVie (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Baxter BioPharma Solutions (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global Pharmaceutical Contract Manufacturing Sale, by Type, Application, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Pharmaceutical Contract Manufacturing (Value)
      • 7.2.1. Global Pharmaceutical Contract Manufacturing by: Type (Value)
        • 7.2.1.1. Active Pharmaceutical Ingredients [API]
        • 7.2.1.2. Finished Dosage Formulations (FDF) [Tablet, Capsule, Oral Liquids, Parenteral/Injectable, Others]
        • 7.2.1.3. Advanced Drug Delivery Products
        • 7.2.1.4. Over The Counter [OTC] Medicines and Nutritional Products
        • 7.2.1.5. Others
      • 7.2.2. Global Pharmaceutical Contract Manufacturing by: Application (Value)
        • 7.2.2.1. Pharmaceutical
        • 7.2.2.2. Biopharmaceutical
      • 7.2.3. Global Pharmaceutical Contract Manufacturing by: End User (Value)
        • 7.2.3.1. Sterile
        • 7.2.3.2. Non-sterile
      • 7.2.4. Global Pharmaceutical Contract Manufacturing Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pharmaceutical Contract Manufacturing: by Type(USD Million)
  • Table 2. Pharmaceutical Contract Manufacturing Active Pharmaceutical Ingredients [API] , by Region USD Million (2015-2020)
  • Table 3. Pharmaceutical Contract Manufacturing Finished Dosage Formulations (FDF) [Tablet, Capsule, Oral Liquids, Parenteral/Injectable, Others] , by Region USD Million (2015-2020)
  • Table 4. Pharmaceutical Contract Manufacturing Advanced Drug Delivery Products , by Region USD Million (2015-2020)
  • Table 5. Pharmaceutical Contract Manufacturing Over The Counter [OTC] Medicines and Nutritional Products , by Region USD Million (2015-2020)
  • Table 6. Pharmaceutical Contract Manufacturing Others , by Region USD Million (2015-2020)
  • Table 7. Pharmaceutical Contract Manufacturing: by Application(USD Million)
  • Table 8. Pharmaceutical Contract Manufacturing Pharmaceutical , by Region USD Million (2015-2020)
  • Table 9. Pharmaceutical Contract Manufacturing Biopharmaceutical , by Region USD Million (2015-2020)
  • Table 10. Pharmaceutical Contract Manufacturing: by End User(USD Million)
  • Table 11. Pharmaceutical Contract Manufacturing Sterile , by Region USD Million (2015-2020)
  • Table 12. Pharmaceutical Contract Manufacturing Non-sterile , by Region USD Million (2015-2020)
  • Table 13. South America Pharmaceutical Contract Manufacturing, by Country USD Million (2015-2020)
  • Table 14. South America Pharmaceutical Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 15. South America Pharmaceutical Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 16. South America Pharmaceutical Contract Manufacturing, by End User USD Million (2015-2020)
  • Table 17. Brazil Pharmaceutical Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 18. Brazil Pharmaceutical Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 19. Brazil Pharmaceutical Contract Manufacturing, by End User USD Million (2015-2020)
  • Table 20. Argentina Pharmaceutical Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 21. Argentina Pharmaceutical Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 22. Argentina Pharmaceutical Contract Manufacturing, by End User USD Million (2015-2020)
  • Table 23. Rest of South America Pharmaceutical Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 24. Rest of South America Pharmaceutical Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 25. Rest of South America Pharmaceutical Contract Manufacturing, by End User USD Million (2015-2020)
  • Table 26. Asia Pacific Pharmaceutical Contract Manufacturing, by Country USD Million (2015-2020)
  • Table 27. Asia Pacific Pharmaceutical Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 28. Asia Pacific Pharmaceutical Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 29. Asia Pacific Pharmaceutical Contract Manufacturing, by End User USD Million (2015-2020)
  • Table 30. China Pharmaceutical Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 31. China Pharmaceutical Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 32. China Pharmaceutical Contract Manufacturing, by End User USD Million (2015-2020)
  • Table 33. Japan Pharmaceutical Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 34. Japan Pharmaceutical Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 35. Japan Pharmaceutical Contract Manufacturing, by End User USD Million (2015-2020)
  • Table 36. India Pharmaceutical Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 37. India Pharmaceutical Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 38. India Pharmaceutical Contract Manufacturing, by End User USD Million (2015-2020)
  • Table 39. Rest of Asia-Pacific Pharmaceutical Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 40. Rest of Asia-Pacific Pharmaceutical Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 41. Rest of Asia-Pacific Pharmaceutical Contract Manufacturing, by End User USD Million (2015-2020)
  • Table 42. Europe Pharmaceutical Contract Manufacturing, by Country USD Million (2015-2020)
  • Table 43. Europe Pharmaceutical Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 44. Europe Pharmaceutical Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 45. Europe Pharmaceutical Contract Manufacturing, by End User USD Million (2015-2020)
  • Table 46. Germany Pharmaceutical Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 47. Germany Pharmaceutical Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 48. Germany Pharmaceutical Contract Manufacturing, by End User USD Million (2015-2020)
  • Table 49. France Pharmaceutical Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 50. France Pharmaceutical Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 51. France Pharmaceutical Contract Manufacturing, by End User USD Million (2015-2020)
  • Table 52. Italy Pharmaceutical Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 53. Italy Pharmaceutical Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 54. Italy Pharmaceutical Contract Manufacturing, by End User USD Million (2015-2020)
  • Table 55. United Kingdom Pharmaceutical Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 56. United Kingdom Pharmaceutical Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 57. United Kingdom Pharmaceutical Contract Manufacturing, by End User USD Million (2015-2020)
  • Table 58. Rest of Europe Pharmaceutical Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 59. Rest of Europe Pharmaceutical Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 60. Rest of Europe Pharmaceutical Contract Manufacturing, by End User USD Million (2015-2020)
  • Table 61. MEA Pharmaceutical Contract Manufacturing, by Country USD Million (2015-2020)
  • Table 62. MEA Pharmaceutical Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 63. MEA Pharmaceutical Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 64. MEA Pharmaceutical Contract Manufacturing, by End User USD Million (2015-2020)
  • Table 65. Middle East Pharmaceutical Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 66. Middle East Pharmaceutical Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 67. Middle East Pharmaceutical Contract Manufacturing, by End User USD Million (2015-2020)
  • Table 68. Africa Pharmaceutical Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 69. Africa Pharmaceutical Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 70. Africa Pharmaceutical Contract Manufacturing, by End User USD Million (2015-2020)
  • Table 71. North America Pharmaceutical Contract Manufacturing, by Country USD Million (2015-2020)
  • Table 72. North America Pharmaceutical Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 73. North America Pharmaceutical Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 74. North America Pharmaceutical Contract Manufacturing, by End User USD Million (2015-2020)
  • Table 75. United States Pharmaceutical Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 76. United States Pharmaceutical Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 77. United States Pharmaceutical Contract Manufacturing, by End User USD Million (2015-2020)
  • Table 78. Canada Pharmaceutical Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 79. Canada Pharmaceutical Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 80. Canada Pharmaceutical Contract Manufacturing, by End User USD Million (2015-2020)
  • Table 81. Mexico Pharmaceutical Contract Manufacturing, by Type USD Million (2015-2020)
  • Table 82. Mexico Pharmaceutical Contract Manufacturing, by Application USD Million (2015-2020)
  • Table 83. Mexico Pharmaceutical Contract Manufacturing, by End User USD Million (2015-2020)
  • Table 84. Company Basic Information, Sales Area and Its Competitors
  • Table 85. Company Basic Information, Sales Area and Its Competitors
  • Table 86. Company Basic Information, Sales Area and Its Competitors
  • Table 87. Company Basic Information, Sales Area and Its Competitors
  • Table 88. Company Basic Information, Sales Area and Its Competitors
  • Table 89. Company Basic Information, Sales Area and Its Competitors
  • Table 90. Company Basic Information, Sales Area and Its Competitors
  • Table 91. Company Basic Information, Sales Area and Its Competitors
  • Table 92. Company Basic Information, Sales Area and Its Competitors
  • Table 93. Company Basic Information, Sales Area and Its Competitors
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Pharmaceutical Contract Manufacturing: by Type(USD Million)
  • Table 100. Pharmaceutical Contract Manufacturing Active Pharmaceutical Ingredients [API] , by Region USD Million (2021-2026)
  • Table 101. Pharmaceutical Contract Manufacturing Finished Dosage Formulations (FDF) [Tablet, Capsule, Oral Liquids, Parenteral/Injectable, Others] , by Region USD Million (2021-2026)
  • Table 102. Pharmaceutical Contract Manufacturing Advanced Drug Delivery Products , by Region USD Million (2021-2026)
  • Table 103. Pharmaceutical Contract Manufacturing Over The Counter [OTC] Medicines and Nutritional Products , by Region USD Million (2021-2026)
  • Table 104. Pharmaceutical Contract Manufacturing Others , by Region USD Million (2021-2026)
  • Table 105. Pharmaceutical Contract Manufacturing: by Application(USD Million)
  • Table 106. Pharmaceutical Contract Manufacturing Pharmaceutical , by Region USD Million (2021-2026)
  • Table 107. Pharmaceutical Contract Manufacturing Biopharmaceutical , by Region USD Million (2021-2026)
  • Table 108. Pharmaceutical Contract Manufacturing: by End User(USD Million)
  • Table 109. Pharmaceutical Contract Manufacturing Sterile , by Region USD Million (2021-2026)
  • Table 110. Pharmaceutical Contract Manufacturing Non-sterile , by Region USD Million (2021-2026)
  • Table 111. South America Pharmaceutical Contract Manufacturing, by Country USD Million (2021-2026)
  • Table 112. South America Pharmaceutical Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 113. South America Pharmaceutical Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 114. South America Pharmaceutical Contract Manufacturing, by End User USD Million (2021-2026)
  • Table 115. Brazil Pharmaceutical Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 116. Brazil Pharmaceutical Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 117. Brazil Pharmaceutical Contract Manufacturing, by End User USD Million (2021-2026)
  • Table 118. Argentina Pharmaceutical Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 119. Argentina Pharmaceutical Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 120. Argentina Pharmaceutical Contract Manufacturing, by End User USD Million (2021-2026)
  • Table 121. Rest of South America Pharmaceutical Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 122. Rest of South America Pharmaceutical Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 123. Rest of South America Pharmaceutical Contract Manufacturing, by End User USD Million (2021-2026)
  • Table 124. Asia Pacific Pharmaceutical Contract Manufacturing, by Country USD Million (2021-2026)
  • Table 125. Asia Pacific Pharmaceutical Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 126. Asia Pacific Pharmaceutical Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 127. Asia Pacific Pharmaceutical Contract Manufacturing, by End User USD Million (2021-2026)
  • Table 128. China Pharmaceutical Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 129. China Pharmaceutical Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 130. China Pharmaceutical Contract Manufacturing, by End User USD Million (2021-2026)
  • Table 131. Japan Pharmaceutical Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 132. Japan Pharmaceutical Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 133. Japan Pharmaceutical Contract Manufacturing, by End User USD Million (2021-2026)
  • Table 134. India Pharmaceutical Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 135. India Pharmaceutical Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 136. India Pharmaceutical Contract Manufacturing, by End User USD Million (2021-2026)
  • Table 137. Rest of Asia-Pacific Pharmaceutical Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 138. Rest of Asia-Pacific Pharmaceutical Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 139. Rest of Asia-Pacific Pharmaceutical Contract Manufacturing, by End User USD Million (2021-2026)
  • Table 140. Europe Pharmaceutical Contract Manufacturing, by Country USD Million (2021-2026)
  • Table 141. Europe Pharmaceutical Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 142. Europe Pharmaceutical Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 143. Europe Pharmaceutical Contract Manufacturing, by End User USD Million (2021-2026)
  • Table 144. Germany Pharmaceutical Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 145. Germany Pharmaceutical Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 146. Germany Pharmaceutical Contract Manufacturing, by End User USD Million (2021-2026)
  • Table 147. France Pharmaceutical Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 148. France Pharmaceutical Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 149. France Pharmaceutical Contract Manufacturing, by End User USD Million (2021-2026)
  • Table 150. Italy Pharmaceutical Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 151. Italy Pharmaceutical Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 152. Italy Pharmaceutical Contract Manufacturing, by End User USD Million (2021-2026)
  • Table 153. United Kingdom Pharmaceutical Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 154. United Kingdom Pharmaceutical Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 155. United Kingdom Pharmaceutical Contract Manufacturing, by End User USD Million (2021-2026)
  • Table 156. Rest of Europe Pharmaceutical Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 157. Rest of Europe Pharmaceutical Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 158. Rest of Europe Pharmaceutical Contract Manufacturing, by End User USD Million (2021-2026)
  • Table 159. MEA Pharmaceutical Contract Manufacturing, by Country USD Million (2021-2026)
  • Table 160. MEA Pharmaceutical Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 161. MEA Pharmaceutical Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 162. MEA Pharmaceutical Contract Manufacturing, by End User USD Million (2021-2026)
  • Table 163. Middle East Pharmaceutical Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 164. Middle East Pharmaceutical Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 165. Middle East Pharmaceutical Contract Manufacturing, by End User USD Million (2021-2026)
  • Table 166. Africa Pharmaceutical Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 167. Africa Pharmaceutical Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 168. Africa Pharmaceutical Contract Manufacturing, by End User USD Million (2021-2026)
  • Table 169. North America Pharmaceutical Contract Manufacturing, by Country USD Million (2021-2026)
  • Table 170. North America Pharmaceutical Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 171. North America Pharmaceutical Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 172. North America Pharmaceutical Contract Manufacturing, by End User USD Million (2021-2026)
  • Table 173. United States Pharmaceutical Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 174. United States Pharmaceutical Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 175. United States Pharmaceutical Contract Manufacturing, by End User USD Million (2021-2026)
  • Table 176. Canada Pharmaceutical Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 177. Canada Pharmaceutical Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 178. Canada Pharmaceutical Contract Manufacturing, by End User USD Million (2021-2026)
  • Table 179. Mexico Pharmaceutical Contract Manufacturing, by Type USD Million (2021-2026)
  • Table 180. Mexico Pharmaceutical Contract Manufacturing, by Application USD Million (2021-2026)
  • Table 181. Mexico Pharmaceutical Contract Manufacturing, by End User USD Million (2021-2026)
  • Table 182. Research Programs/Design for This Report
  • Table 183. Key Data Information from Secondary Sources
  • Table 184. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pharmaceutical Contract Manufacturing: by Type USD Million (2015-2020)
  • Figure 5. Global Pharmaceutical Contract Manufacturing: by Application USD Million (2015-2020)
  • Figure 6. Global Pharmaceutical Contract Manufacturing: by End User USD Million (2015-2020)
  • Figure 7. South America Pharmaceutical Contract Manufacturing Share (%), by Country
  • Figure 8. Asia Pacific Pharmaceutical Contract Manufacturing Share (%), by Country
  • Figure 9. Europe Pharmaceutical Contract Manufacturing Share (%), by Country
  • Figure 10. MEA Pharmaceutical Contract Manufacturing Share (%), by Country
  • Figure 11. North America Pharmaceutical Contract Manufacturing Share (%), by Country
  • Figure 12. Global Pharmaceutical Contract Manufacturing share by Players 2020 (%)
  • Figure 13. Global Pharmaceutical Contract Manufacturing share by Players (Top 3) 2020(%)
  • Figure 14. Global Pharmaceutical Contract Manufacturing share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 17. Thermo Fisher Scientific (United States) Revenue: by Geography 2020
  • Figure 18. Catalent (United States) Revenue, Net Income and Gross profit
  • Figure 19. Catalent (United States) Revenue: by Geography 2020
  • Figure 20. Lonza (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Lonza (Switzerland) Revenue: by Geography 2020
  • Figure 22. Evonik Industries (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Evonik Industries (Germany) Revenue: by Geography 2020
  • Figure 24. Teva Pharmaceutical Industries (Israel) Revenue, Net Income and Gross profit
  • Figure 25. Teva Pharmaceutical Industries (Israel) Revenue: by Geography 2020
  • Figure 26. Boehringer Ingelheim BioXcellence (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Boehringer Ingelheim BioXcellence (Germany) Revenue: by Geography 2020
  • Figure 28. Famar S.A. (Greece) Revenue, Net Income and Gross profit
  • Figure 29. Famar S.A. (Greece) Revenue: by Geography 2020
  • Figure 30. Fareva Group (France) Revenue, Net Income and Gross profit
  • Figure 31. Fareva Group (France) Revenue: by Geography 2020
  • Figure 32. Vetter Pharma International (Germany) Revenue, Net Income and Gross profit
  • Figure 33. Vetter Pharma International (Germany) Revenue: by Geography 2020
  • Figure 34. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 35. Mylan (United States) Revenue: by Geography 2020
  • Figure 36. Recipharm (Sweden) Revenue, Net Income and Gross profit
  • Figure 37. Recipharm (Sweden) Revenue: by Geography 2020
  • Figure 38. Aesica Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 39. Aesica Pharmaceuticals (United Kingdom) Revenue: by Geography 2020
  • Figure 40. Pharmaceutical Product Development LLC (United States) Revenue, Net Income and Gross profit
  • Figure 41. Pharmaceutical Product Development LLC (United States) Revenue: by Geography 2020
  • Figure 42. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 43. AbbVie (United States) Revenue: by Geography 2020
  • Figure 44. Baxter BioPharma Solutions (United States) Revenue, Net Income and Gross profit
  • Figure 45. Baxter BioPharma Solutions (United States) Revenue: by Geography 2020
  • Figure 46. Global Pharmaceutical Contract Manufacturing: by Type USD Million (2021-2026)
  • Figure 47. Global Pharmaceutical Contract Manufacturing: by Application USD Million (2021-2026)
  • Figure 48. Global Pharmaceutical Contract Manufacturing: by End User USD Million (2021-2026)
  • Figure 49. South America Pharmaceutical Contract Manufacturing Share (%), by Country
  • Figure 50. Asia Pacific Pharmaceutical Contract Manufacturing Share (%), by Country
  • Figure 51. Europe Pharmaceutical Contract Manufacturing Share (%), by Country
  • Figure 52. MEA Pharmaceutical Contract Manufacturing Share (%), by Country
  • Figure 53. North America Pharmaceutical Contract Manufacturing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Thermo Fisher Scientific (United States)
  • Catalent (United States)
  • Lonza (Switzerland)
  • Evonik Industries (Germany)
  • Teva Pharmaceutical Industries (Israel)
  • Boehringer Ingelheim BioXcellence (Germany)
  • Famar S.A. (Greece)
  • Fareva Group (France)
  • Vetter Pharma International (Germany)
  • Mylan (United States)
  • Recipharm (Sweden)
  • Aesica Pharmaceuticals (United Kingdom)
  • Pharmaceutical Product Development LLC (United States)
  • AbbVie (United States)
  • Baxter BioPharma Solutions (United States)
Additional players considered in the study are as follows:
QuintilesIMS (United States) , Dalton Pharma Services (Canada) , Grifols S.A (Spain) , Ligand Pharmaceuticals, Inc. (United States) , Valeant Pharmaceuticals International Inc. (Canada) , West Pharmaceutical Services, Inc. (United States)
Select User Access Type

Key Highlights of Report


Oct 2021 240 Pages 51 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pharmaceutical Contract Manufacturing Market Quantitative research analysis
Global Pharmaceutical Contract Manufacturing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Pharmaceutical Contract Manufacturing study can be customized to meet your requirements. The market size breakdown by type [Active Pharmaceutical Ingredients [API], Finished Dosage Formulations (FDF) [Tablet, Capsule, Oral Liquids, Parenteral/Injectable, Others], Advanced Drug Delivery Products, Over The Counter [OTC] Medicines and Nutritional Products and Others], by end use application [Pharmaceutical and Biopharmaceutical].
The Pharmaceutical Contract Manufacturing Market is gaining popularity and expected to see strong valuation by 2026.
According to AMA, the Global Pharmaceutical Contract Manufacturing market is expected to see growth rate of 7.5%.

Know More About Global Pharmaceutical Contract Manufacturing Market Report?

Have a Query? Click Here

Other Related Reports

Bioinformatics Comprehensive Study by Type (Knowledge Management Tools, Bioinformatics Platforms, Bioinformatics Services), Application (Genomics, Chemoinformatics & Drug design, Proteomics, Transcri...
$ 3750
Vaccine Contract Manufacturing Comprehensive Study by Type (Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines), Application (Mammalian, Microbial, Others), Scal...
$ 3750
Clinical Trial Management System (CTMS) Comprehensive Study by Type (Enterprise CTMS, Site CTMS), Application (Pharmaceutical and Biopharmaceutical Companies, Contract Research Organizations (CRO), M...
$ 3750
Drug Discovery Comprehensive Study by Type (Small Molecule Drug, Biologics Drug), Technology (High Throughput Screening, Pharmacogenomics, Combinatorial Chemistry, Nanotechnology, Other Technologies)...
$ 3450
Live Cell Encapsulation Comprehensive Study by Type (Alginate, HEMA-MMA (Hydroxyethyl Methacrylate-methyl Methacrylate), Siliceous Encapsulates, Cellulose Sulfate, PAN-PVC (Acrylonitrile Vinyl Chlori...
$ 3750
DNA 3D Printing Comprehensive Study by Type (3D Printer, Laser Technology, DNA Sample, Enzyme), Application (Bioengineering / R&D, Pharmaceutical Drugs/ Therapies, Agriculture Industry, Energy, Other...
$ 3650